Rajat Thawani

Dr. Rajat Thawani

Knight Cancer Institute, Oregon Health & Science University, Portland, Connecticut, USA
orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2018 in Lung Cancer
Verified
Journal Article
Closed access
Rajat ThawaniRajat Thawani
Rajat Thawani
MMMichael McLane
Michael McLane
NBNiha Beig
Niha Beig
SGSoumya Ghose
Soumya Ghose
PPPrateek Prasanna
Prateek Prasanna
Anant MadabhushiAnant Madabhushi
Anant Madabhushi

1 January 2020 in Cancer Immunology Research
Verified
Journal Article
Closed access
PDF file
MKMohammadhadi Khorrami
Mohammadhadi Khorrami
PPPrateek Prasanna
Prateek Prasanna
AGAmit Gupta
Amit Gupta
PPPradnya Patil
Pradnya Patil
PVPriya D. Velu
Priya D. Velu
Anant MadabhushiAnant Madabhushi
Anant Madabhushi
No predictive biomarkers can robustly identify patients with non–small cell lung cancer (NSCLC) who will benefit from immune checkpoint inhibitor (ICI) therapies. Here, in a machine learning setting, we compared changes (“delta”) in the radiomic texture (DelRADx) of CT patterns both within and outside tumor nodules before and after two to three cycles of ICI therapy. We found that DelRADx patterns could predict response to ICI therapy and overall survival (OS) for patients with NSCLC. We retrospectively analyzed data acquired from 139 patients with NSCLC at two institutions, who were divided into a discovery set (D1 = 50) and two independent validation sets (D2 = 62, D3 = 27). Intranodular and perinodular texture descriptors were extracted, and the relative differences were computed. A linear discriminant analysis (LDA) classifier was trained with 8 DelRADx features to predict RECIST-derived response. Association of delta-radiomic risk score (DRS) with OS was determined. The association of DelRADx features with tumor-infiltrating lymphocyte (TIL) density on the diagnostic biopsies (n = 36) was also evaluated. The LDA classifier yielded an AUC of 0.88 ± 0.08 in distinguishing responders from nonresponders in D1, and 0.85 and 0.81 in D2 and D3. DRS was associated with OS [HR: 1.64; 95% confidence interval (CI), 1.22–2.21; P = 0.0011; C-index = 0.72). Peritumoral Gabor features were associated with the density of TILs on diagnostic biopsy samples. Our results show that DelRADx could be used to identify early functional responses in patients with NSCLC.

2 August 2022 in CA: A Cancer Journal for Clinicians
Verified
Journal Article
Open access
Rajat ThawaniRajat Thawani
Rajat Thawani
MKMyung Sun Kim
Myung Sun Kim
AAAsad Arastu
Asad Arastu
ZFZizhen Feng
Zizhen Feng
MWMalinda T. West
Malinda T. West
RCRavi A. Chandra
Ravi A. Chandra
Sinonasal malignancies make up <5% of all head and neck neoplasms, with an incidence of 0.5–1.0 per 100,000. The outcome of these rare malignancies has been poor, whereas significant progress has been made in the management of other cancers. The objective of the current review was to describe the incidence, causes, presentation, diagnosis, treatment, and recent developments of malignancies of the sinonasal tract. The diagnoses covered in this review included sinonasal undifferentiated carcinoma, sinonasal adenocarcinoma, sinonasal squamous cell carcinoma, and esthesioneuroblastoma, which are exclusive to the sinonasal tract. In addition, the authors covered malignances that are likely to be encountered in the sinonasal tract—primary mucosal melanoma, NUT (nuclear protein of the testis) carcinoma, and extranodal natural killer cell/T‐cell lymphoma. For the purpose of keeping this review as concise and focused as possible, sarcomas and malignancies that can be classified as salivary gland neoplasms were excluded.

19 October 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
XWXiangxue Wang
Xiangxue Wang
AJAndrew Janowczyk
Andrew Janowczyk
YZYu Zhou
Yu Zhou
Rajat ThawaniRajat Thawani
Rajat Thawani
PFPingfu FU
Pingfu FU
Anant MadabhushiAnant Madabhushi
Anant Madabhushi
Identification of patients with early stage non-small cell lung cancer (NSCLC) with high risk of recurrence could help identify patients who would receive additional benefit from adjuvant therapy. In this work, we present a computational histomorphometric image classifier using nuclear orientation, texture, shape, and tumor architecture to predict disease recurrence in early stage NSCLC from digitized H&E tissue microarray (TMA) slides. Using a retrospective cohort of early stage NSCLC patients (Cohort #1, n = 70), we constructed a supervised classification model involving the most predictive features associated with disease recurrence. This model was then validated on two independent sets of early stage NSCLC patients, Cohort #2 (n = 119) and Cohort #3 (n = 116). The model yielded an accuracy of 81% for prediction of recurrence in the training Cohort #1, 82% and 75% in the validation Cohorts #2 and #3 respectively. A multivariable Cox proportional hazard model of Cohort #2, incorporating gender and traditional prognostic variables such as nodal status and stage indicated that the computer extracted histomorphometric score was an independent prognostic factor (hazard ratio = 20.81, 95% CI: 6.42–67.52, P < 0.001).

1 March 2019 in Radiology: Artificial Intelligence
Verified
Journal Article
Closed access
MKMohammadhadi Khorrami
Mohammadhadi Khorrami
MKMonica Khunger
Monica Khunger
AZAlexia Zagouras
Alexia Zagouras
PPPradnya Patil
Pradnya Patil
Rajat ThawaniRajat Thawani
Rajat Thawani
AMAnant Madabhushi
Anant Madabhushi
PurposeTo identify the role of radiomics texture features both within and outside the nodule in predicting (a) time to progression (TTP) and overall survival (OS) as well as (b) response to chemotherapy in patients with non–small cell lung cancer (NSCLC).Materials and MethodsData in a total of 125 patients who had been treated with pemetrexed-based platinum doublet chemotherapy at Cleveland Clinic were retrospectively analyzed. The patients were divided randomly into two sets with the constraint that there were an equal number of responders and nonresponders in the training set. The training set comprised 53 patients with NSCLC, and the validation set comprised 72 patients. A machine learning classifier trained with radiomic texture features extracted from intra- and peritumoral regions of non–contrast-enhanced CT images was used to predict response to chemotherapy. The radiomic risk-score signature was generated by using least absolute shrinkage and selection operator with the Cox regression model; assoc...

1 November 2018 in American Journal of Neuroradiology
Verified
Journal Article
Open access
PDF file
MIMarwa Ismail
Marwa Ismail
VHVirginia Boyce Hill
Virginia Boyce Hill
VSV. Statsevych
V. Statsevych
RHR. Huang
R. Huang
PPPrateek Prasanna
Prateek Prasanna
PTP. Tiwari
P. Tiwari
BACKGROUND AND PURPOSE: Differentiating pseudoprogression, a radiation-induced treatment effect, from tumor progression on imaging is a substantial challenge in glioblastoma management. Unfortunately, guidelines set by the Response Assessment in Neuro-Oncology criteria are based solely on bidirectional diametric measurements of enhancement observed on T1WI and T2WI/FLAIR scans. We hypothesized that quantitative 3D shape features of the enhancing lesion on T1WI, and T2WI/FLAIR hyperintensities (together called the lesion habitat) can more comprehensively capture pathophysiologic differences across pseudoprogression and tumor recurrence, not appreciable on diametric measurements alone. MATERIALS AND METHODS: A total of 105 glioblastoma studies from 2 institutions were analyzed, consisting of a training (n = 59) and an independent test (n = 46) cohort. For every study, expert delineation of the lesion habitat (T1WI enhancing lesion and T2WI/FLAIR hyperintense perilesional region) was obtained, followed by extraction of 30 shape features capturing 14 “global” contour characteristics and 16 “local” curvature measures for every habitat region. Feature selection was used to identify most discriminative features on the training cohort, which were evaluated on the test cohort using a support vector machine classifier. RESULTS: The top 2 most discriminative features were identified as local features capturing total curvature of the enhancing lesion and curvedness of the T2WI/FLAIR hyperintense perilesional region. Using top features from the training cohort (training accuracy = 91.5%), we obtained an accuracy of 90.2% on the test set in distinguishing pseudoprogression from tumor progression. CONCLUSIONS: Our preliminary results suggest that 3D shape attributes from the lesion habitat can differentially express across pseudoprogression and tumor progression and could be used to distinguish these radiographically similar pathologies.